Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management
This article was originally published in RPM Report
Executive Summary
A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.
You may also be interested in...
Second-Guessing FDA: CMS' Expanding Regulatory Role
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.
Synagis' Special Status Under Health Care Reform
The new Medicaid rebate rules don’t bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune’s Synagis is the only therapy to qualify.
Second-Guessing FDA: CMS' Expanding Regulatory Role
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.